Products

Zitomycin (Mitomycin Injection) – Product Description Zitomycin contains Mitomycin, a prescription anti-cancer (chemotherapy) medicine used in the treatment of various solid tumors, including gastric (stomach) cancer, pancreatic cancer, and bladder cancer. It belongs to the antitumor antibiotic class of chemotherapy agents and works by preventing cancer cells from growing and multiplying through DNA cross-linking, ultimately leading to cancer cell death. Mitomycin is administered by qualified healthcare professionals as an intravenous (IV) injection or, for certain bladder cancers, as intravesical therapy directly into the bladder. It may be used alone or in combination with other chemotherapy medicines depending on the patient's condition and treatment protocol. Active Ingredient Mitomycin Dosage Form Sterile Injection Therapeutic Indications Gastric (Stomach) Cancer Pancreatic Cancer Superficial Bladder Cancer (Intravesical Therapy) Other cancers as recommended by an oncologist How It Works Mitomycin acts by forming DNA cross-links, which prevent cancer cells from replicating and repairing their DNA. This inhibits cell division and promotes the destruction of rapidly growing cancer cells. Key Features Broad-spectrum chemotherapy agent Effective in selected gastrointestinal and bladder cancers Suitable for use as monotherapy or in combination chemotherapy Administered under specialist medical supervision Manufactured according to stringent pharmaceutical quality standards Storage Store as directed by the manufacturer. Protect from light and excessive heat. Keep out of reach of children. Note: Zitomycin (Mitomycin Injection) is a prescription-only chemotherapy medicine and should only be administered by qualified healthcare professionals experienced in oncology. Regular monitoring of blood counts, kidney function, and overall health is essential during treatment.

Zinotecan (Irinotecan Injection) – Product Description Zinotecan contains Irinotecan, a prescription anti-cancer (chemotherapy) medicine used to treat advanced or metastatic colorectal cancer and certain other cancers as recommended by an oncologist. It belongs to the topoisomerase I inhibitor class of chemotherapy drugs and works by interfering with the DNA replication process in rapidly dividing cancer cells, helping to slow or stop their growth. Zinotecan is administered as an intravenous (IV) infusion by trained healthcare professionals, either alone or in combination with other chemotherapy medicines such as 5-Fluorouracil (5-FU) and Leucovorin. Treatment schedules and dosage are determined by the patient's condition, body surface area, and overall treatment plan. Active Ingredient Irinotecan Hydrochloride Dosage Form Sterile Injection for Intravenous (IV) Infusion Therapeutic Indications Metastatic Colorectal Cancer Advanced Colorectal Cancer Other solid tumors, as determined by the treating oncologist How It Works Irinotecan inhibits the topoisomerase I enzyme, preventing cancer cells from repairing damaged DNA during cell division. This results in cancer cell death and helps reduce tumor growth. Key Features Effective chemotherapy for colorectal cancer Can be used as monotherapy or combination therapy Administered under medical supervision Manufactured according to stringent pharmaceutical quality standards Intended for hospital and oncology clinic use Storage Store according to the manufacturer's recommendations. Protect from excessive heat and light. Keep out of reach of children. Note: Zinotecan (Irinotecan Injection) is a prescription-only chemotherapy medicine and should be administered only by qualified healthcare professionals experienced in cancer treatment. Regular monitoring of blood counts and overall health is required throughout therapy.

Zimitib Cap (Imatinib 100 mg) – Product Description Zimitib Cap contains Imatinib 100 mg, a targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. It is primarily prescribed for the treatment of specific blood cancers and certain solid tumors by blocking abnormal proteins that promote the growth and multiplication of cancer cells. This targeted mechanism helps slow disease progression while preserving healthy cells more effectively than traditional chemotherapy. Active Ingredient Imatinib Mesylate 100 mg Dosage Form Oral Capsule Therapeutic Indications Zimitib Cap is prescribed for the treatment of: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Gastrointestinal Stromal Tumors (GIST) Myelodysplastic/Myeloproliferative Disorders (MDS/MPD) Hypereosinophilic Syndrome (HES) Dermatofibrosarcoma Protuberans (DFSP), as recommended by an oncologist. How It Works Imatinib inhibits specific tyrosine kinase enzymes, including the BCR-ABL protein, which is responsible for uncontrolled cancer cell growth. By blocking these enzymes, it slows or stops the proliferation of cancer cells and helps manage the disease. Key Features Targeted therapy for selected cancers Effective oral treatment option Helps control disease progression Suitable for long-term treatment under medical supervision Widely used in oncology treatment protocols Directions for Use Take exactly as prescribed by your oncologist. Swallow the capsule whole with a full glass of water. Take with food to minimize stomach irritation. Do not miss doses or discontinue treatment without consulting your physician. Storage Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Important Safety Information Common side effects may include: Nausea or vomiting Diarrhea Muscle cramps Swelling (fluid retention) Fatigue Skin rash Regular monitoring of blood counts and liver function is recommended during treatment. Contact your healthcare provider immediately if you experience severe swelling, unusual bleeding, fever, or signs of liver problems. Note: Zimitib Cap (Imatinib 100 mg) is a prescription-only medicine and should only be used under the supervision of a qualified oncologist.

Zetabin Injection (Gemcitabine Injection) – Product Description Zetabin Injection contains Gemcitabine, a nucleoside analog chemotherapy medicine used in the treatment of various types of cancers. It works by interfering with the growth and multiplication of cancer cells, helping to slow down or stop tumor progression. Gemcitabine is widely used as part of chemotherapy protocols for cancers including pancreatic cancer, non-small cell lung cancer, breast cancer, ovarian cancer, and bladder cancer. It may be used alone or in combination with other anticancer medicines depending on the patient's condition and treatment plan. Zetabin Injection is administered by a qualified healthcare professional through intravenous infusion. The dosage, frequency, and duration of treatment are determined by the treating oncologist based on cancer type, patient health condition, and response to therapy. Key Features: Contains Gemcitabine as the active anticancer ingredient Belongs to the class of antimetabolite chemotherapy agents Used in multiple solid tumor treatment protocols Administered through intravenous infusion under medical supervision Suitable for hospital and oncology center use Manufactured following stringent pharmaceutical quality standards Therapeutic Uses: Pancreatic Cancer Non-Small Cell Lung Cancer (NSCLC) Breast Cancer Ovarian Cancer Bladder Cancer Other malignancies as prescribed by an oncologist Important Note: Zetabin Injection is a prescription chemotherapy medicine and should only be used under the supervision of a qualified oncologist. Regular monitoring of blood counts and patient condition is required during treatment.

Zepirubin Injection contains Epirubicin, an anthracycline chemotherapy medicine used in the treatment of various cancers. It works by interfering with the growth and multiplication of cancer cells, helping to slow down or stop cancer progression. Epirubicin is commonly used as part of combination chemotherapy regimens and is administered under the supervision of an experienced oncologist. It is widely used in the management of breast cancer and other solid tumors where anthracycline-based therapy is clinically appropriate. Key Features: Contains Epirubicin Hydrochloride as the active ingredient Belongs to the Anthracycline class of anticancer medicines Injectable formulation for hospital and oncology center use Used in combination chemotherapy protocols Helps inhibit cancer cell growth and DNA replication Manufactured under strict pharmaceutical quality standards Therapeutic Uses: Breast Cancer Gastric Cancer Ovarian Cancer Lung Cancer Soft Tissue Sarcoma Other solid tumors as determined by an oncologist Product Information: Brand Name: Zepirubin Active Ingredient: Epirubicin Hydrochloride Dosage Form: Injection Therapeutic Class: Oncology / Chemotherapy Medicine Route of Administration: Intravenous infusion (administered by healthcare professionals) Note: Zepirubin Injection should only be used under the supervision of a qualified oncologist. Dosage, treatment cycles, and monitoring requirements are determined based on the patient's condition and response to therapy.

Zefinib Tablet 250 mg contains Gefitinib, a targeted anticancer medicine belonging to the class of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). It works by blocking EGFR signals that contribute to the growth and multiplication of certain cancer cells, helping to slow tumor progression. Gefitinib is primarily used in the treatment of non-small cell lung cancer (NSCLC), especially in patients whose tumors have specific EGFR mutations. It provides a targeted treatment approach by acting on cancer cells with these genetic changes. Zefinib Tablet is taken orally and should be used strictly under the supervision of an experienced oncologist. The treatment duration and dosage may vary depending on the patient's condition, cancer stage, and response to therapy. Key Features: Contains Gefitinib 250 mg Targeted therapy for EGFR-mutated cancers Belongs to the EGFR Tyrosine Kinase Inhibitor (TKI) class Oral tablet formulation for convenient administration Used in advanced oncology treatment protocols Manufactured under quality-controlled pharmaceutical standards Therapeutic Uses: EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Advanced or metastatic lung cancer management (as prescribed) Note: Zefinib Tablet should only be used under the guidance of a qualified oncologist. Regular monitoring and medical follow-up are required during treatment to evaluate response and manage possible adverse effects.

Zedaunor Injection 20 mg contains Daunorubicin, an anthracycline chemotherapy medicine used in the treatment of various blood cancers. It works by interfering with DNA replication inside cancer cells, helping to prevent their growth and multiplication. Daunorubicin is primarily used as part of combination chemotherapy regimens for the treatment of acute leukemias, especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is administered by qualified healthcare professionals in specialized oncology settings. Zedaunor Injection is given through intravenous administration under strict medical supervision. The dosage and treatment schedule are determined by the treating oncologist based on the patient's condition, cancer type, treatment protocol, and overall health status. Key Features: Contains Daunorubicin 20 mg Belongs to the Anthracycline class of chemotherapy medicines Used in hematological malignancies (blood cancers) Injectable formulation for hospital and oncology center use Helps inhibit cancer cell growth by affecting DNA function Manufactured under stringent pharmaceutical quality standards Therapeutic Uses: Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL) Other hematological cancers as recommended by an oncologist Note: Zedaunor Injection should only be administered by trained healthcare professionals. Patients require appropriate monitoring during treatment, including blood counts and cardiac function assessments, as advised by the treating physician.

Zaxotein Injection 100 mg contains Albumin-Bound Paclitaxel (Nab-Paclitaxel) 100 mg, an advanced formulation of the chemotherapy medicine paclitaxel. It belongs to the taxane class of anticancer agents and is designed to interfere with cancer cell division, helping to slow down or stop the growth of malignant cells. Albumin-bound paclitaxel uses an albumin-based delivery system that helps transport paclitaxel to tumor tissues. It is used in the treatment of various solid tumors, including breast cancer, non-small cell lung cancer, pancreatic cancer, and other cancers where taxane therapy is considered appropriate. Zaxotein Injection is administered by intravenous infusion under the supervision of qualified oncology professionals. The dosage schedule is determined by the treating oncologist based on the patient's cancer type, treatment plan, and overall health condition. Key Features: Contains Albumin-Bound Paclitaxel (Nab-Paclitaxel) 100 mg Advanced taxane-based chemotherapy formulation Used in multiple solid tumor treatment protocols Helps inhibit cancer cell growth and division Intravenous formulation for hospital and oncology center use Manufactured under strict pharmaceutical quality standards Suitable for oncology departments, hospitals, and specialized cancer care facilities Therapeutic Uses: Breast Cancer Non-Small Cell Lung Cancer (NSCLC) Pancreatic Cancer Other solid tumors as recommended by an oncologist Note: Zaxotein Injection should only be administered under the supervision of a qualified healthcare professional. Patients require regular monitoring for treatment response and possible chemotherapy-related adverse effects.

Zabiteron Tablet 250 mg contains Abiraterone Acetate 250 mg, an oral anticancer medicine belonging to the class of androgen biosynthesis inhibitors. It is primarily used in the treatment of advanced prostate cancer, particularly in patients with metastatic prostate cancer where reducing androgen production can help slow cancer progression. Abiraterone Acetate works by inhibiting the CYP17 enzyme, which plays an important role in androgen production. By reducing androgen levels in the body, Zabiteron helps limit the growth and spread of prostate cancer cells that depend on male hormones for development. Zabiteron is generally prescribed along with corticosteroid therapy (such as prednisone/prednisolone) and is used under the supervision of an experienced oncologist. The dosage, treatment duration, and monitoring schedule depend on the patient's medical condition and response to therapy. Key Features: Contains Abiraterone Acetate 250 mg Oral hormonal therapy for advanced prostate cancer Belongs to the CYP17 inhibitor class Helps reduce androgen production supporting cancer control Used as part of comprehensive prostate cancer treatment protocols Manufactured under strict pharmaceutical quality standards Suitable for oncology hospitals, clinics, and specialty healthcare providers Therapeutic Uses: Metastatic Castration-Resistant Prostate Cancer (mCRPC) Metastatic Castration-Sensitive Prostate Cancer (mCSPC), as recommended by an oncologist Note: Zabiteron Tablet should only be used under the direction of a qualified healthcare professional. Regular monitoring of liver function, blood pressure, potassium levels, and overall treatment response may be required during therapy.

Z-Blastin Injection (Vinblastine Sulfate 10 mg) – Product Description Z-Blastin Injection 10 mg contains Vinblastine Sulfate, a chemotherapy medicine belonging to the vinca alkaloid group of anticancer agents. It works by interfering with the growth and division of cancer cells, helping to slow down or stop the progression of certain types of cancer. Vinblastine is used as part of combination chemotherapy protocols for various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, testicular cancer, Kaposi sarcoma, and other cancers where vinblastine therapy is considered appropriate by an oncologist. Z-Blastin Injection is administered by a qualified healthcare professional through the appropriate route under medical supervision. The dosage and treatment schedule depend on the patient's cancer type, body condition, and response to therapy. Key Features: Contains Vinblastine Sulfate 10 mg Belongs to the Vinca Alkaloid class of chemotherapy medicines Used in various oncology treatment protocols Injectable formulation for hospital and clinical use Manufactured under strict pharmaceutical quality standards Suitable for oncology centers, hospitals, and healthcare providers Therapeutic Uses: Hodgkin Lymphoma Non-Hodgkin Lymphoma Testicular Cancer Kaposi Sarcoma Other cancers as determined by an oncology specialist Note: Z-Blastin Injection should only be administered under the supervision of a qualified healthcare professional. Treatment decisions, dosage adjustments, and monitoring should be performed by an experienced oncologist.

Ridoxia Tablet 160 mg contains Megestrol Acetate 160 mg, a synthetic progestin primarily prescribed to stimulate appetite and promote weight gain in patients experiencing significant weight loss due to chronic illnesses. It is also used in the treatment of certain hormone-sensitive cancers, including advanced breast cancer and endometrial (uterine) cancer, as directed by an oncologist. Megestrol acetate works by influencing hormone receptors and helping improve appetite, calorie intake, and body weight in eligible patients. In oncology, it may also help slow the growth of certain cancer cells that are responsive to hormonal therapy. Ridoxia Tablet should be taken exactly as prescribed by a qualified healthcare professional. The dosage and duration of treatment depend on the patient's medical condition, treatment goals, and response to therapy. Regular follow-up is important to monitor effectiveness and manage any potential side effects. Key Features Contains Megestrol Acetate 160 mg Used for appetite stimulation and management of significant weight loss in appropriate patients Also indicated for certain hormone-sensitive cancers under specialist supervision Oral tablet for convenient administration Prescription medicine requiring medical supervision Manufactured under quality-controlled pharmaceutical standards Note: Ridoxia Tablet should only be used under the guidance of a healthcare professional. It is not suitable for self-medication, and patients should follow their physician's instructions regarding dosage, duration, and monitoring.

PPTINIB Tablet contains Dasatinib, a prescription tyrosine kinase inhibitor (TKI) used in the treatment of certain types of leukemia. It works by blocking abnormal proteins (BCR-ABL and SRC family kinases) that promote the growth and spread of cancer cells, helping to slow or stop disease progression. Dasatinib is commonly prescribed for adults and children with Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and certain cases of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), as determined by an oncologist or hematologist. PPTINIB Tablets are manufactured under stringent quality standards and are available in multiple strengths to meet different treatment requirements. The tablets should be taken exactly as prescribed by a healthcare professional, with or without food, and treatment should not be discontinued without medical advice. Key Highlights Brand Name: PPTINIB Tablet Generic Name: Dasatinib Dosage Form: Oral Tablets Therapeutic Category: Anti-Cancer / Oncology Medicine Drug Class: Tyrosine Kinase Inhibitor (TKI) Indications: Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) Storage: Store below 30°C in a cool, dry place away from direct sunlight. Prescription Status: Prescription-only medicine. Use only under the supervision of a qualified healthcare professional.